Patents by Inventor Henri-Jacques Delecluse

Henri-Jacques Delecluse has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Epstein-Barr virus-like particles with broadened antigenic spectrum
    Patent number: 11806395
    Abstract: The present invention relates to a preparation comprising Epstein-Barr virus-like particles (EB-VLPs), said EB-VLPs being essentially free of Epstein Barr virus (EBV) DNA, wherein said EB-VLPs comprise a vaccination polypeptide comprising at least one peptide of an EBV tegument polypeptide and at least one immunogenic peptide; and to polynucleotides, host cells, and methods related thereto.
    Type: Grant
    Filed: October 11, 2019
    Date of Patent: November 7, 2023
    Assignee: Deutsches Krebsforschungszentrum
    Inventors: Henri-Jacques Delecluse, Dwain Van Zyl
  • POLYPEPTIDES FOR TREATMENT OF AML
    Publication number: 20220273781
    Abstract: The present invention relates to a polypeptide comprising (i) a binding peptide binding to at least one surface marker of an acute myeloid leukemia (AML) cell, and (ii) an immunogenic peptide comprising at least one T-cell epitope; and to means and methods related thereto.
    Type: Application
    Filed: July 23, 2020
    Publication date: September 1, 2022
    Applicant: Deutsches Krebsforschungszentrum
    Inventors: Henri-Jacques DELECLUSE, Marta ILECKA, Guillaume WASSMER
  • EPSTEIN-BARR VIRUS-LIKE PARTICLES WITH BROADENED ANTIGENIC SPECTRUM
    Publication number: 20210290758
    Abstract: The present invention relates to a preparation comprising Epstein-Barr virus-like particles (EB-VLPs), said EB-VLPs being essentially free of Epstein Barr virus (EBV) DNA, wherein said EB-VLPs comprise a vaccination polypeptide comprising at least one peptide of an EBV tegument polypeptide and at least one immunogenic peptide; and to polynucleotides, host cells, and methods related thereto.
    Type: Application
    Filed: October 11, 2019
    Publication date: September 23, 2021
    Inventors: Henri-Jacques Delecluse, Dwain Van Zyl
  • EBV vaccine
    Patent number: 11097003
    Abstract: The present invention relates to a composition comprising Epstein-Barr Virus (EBV) particles for use in vaccination of a subject, wherein said EBV particles comprise a significantly reduced chromosome instability-inducing EBV polypeptide activity. The present invention also relates to a composition comprising EBV particles for use in vaccination of a subject, wherein said vaccination comprises avoiding contacting the cytosol and/or nucleus of cells of said subject with a chromosome instability-inducing EBV polypeptide activity. Moreover, the present invention relates to polynucleotides, host cells, methods, and uses related to the aforesaid compositions.
    Type: Grant
    Filed: November 10, 2017
    Date of Patent: August 24, 2021
    Assignee: Deutsches Krebsforschungszentrum
    Inventors: Henri-Jacques Delecluse, Anatoliy Shumilov, Ming-Han Tsai
  • B-cell receptor complex binding proteins containing T-cell epitopes
    Patent number: 10961280
    Abstract: The present invention relates to a polypeptide comprising a) a binding peptide binding to at least one protein selected from the group consisting of CD22, CD19, CD20, and CD21, and b) an immunogenic peptide comprising at least one T-cell epitope for use in vaccination of a subject against B-cell hyperproliferation or for use in the modulation of the immune response in a subject. The present invention further relates to a polynucleotide and a vector encoding said polypeptide and a host cell comprising the same.
    Type: Grant
    Filed: July 9, 2018
    Date of Patent: March 30, 2021
    Assignee: Deutsches Krebsforschungszentrum
    Inventors: Henri-Jacques Delecluse, Regina Feederle, Emmalene Bartlett
  • IMPROVED EBV VACCINE
    Publication number: 20190282691
    Abstract: The present invention relates to a composition comprising Epstein-Barr Virus (EBV) particles for use in vaccination of a subject, wherein said EBV particles comprise a significantly reduced chromosome instability-inducing EBV polypeptide activity. The present invention also relates to a composition comprising EBV particles for use in vaccination of a subject, wherein said vaccination comprises avoiding contacting the cytosol and/or nucleus of cells of said subject with a chromosome instability-inducing EBV polypeptide activity. Moreover, the present invention relates to polynucleotides, host cells, methods, and uses related to the aforesaid compositions.
    Type: Application
    Filed: November 10, 2017
    Publication date: September 19, 2019
    Inventors: Henri-Jacques Delecluse, Anatoliy Shumilov, Ming-Han Tsai
  • B-CELL RECEPTOR COMPLEX BINDING PROTEINS CONTAINING T-CELL EPITOPES
    Publication number: 20180312547
    Abstract: The present invention relates to a polypeptide comprising a) a binding peptide binding to at least one protein selected from the group consisting of CD22, CD19, CD20, and CD21, and b) an immunogenic peptide comprising at least one T-cell epitope for use in vaccination of a subject against B-cell hyperproliferation or for use in the modulation of the immune response in a subject. The present invention further relates to a polynucleotide and a vector encoding said polypeptide and a host cell comprising the same.
    Type: Application
    Filed: July 9, 2018
    Publication date: November 1, 2018
    Applicant: Deutsches Krebsforschungszentrum
    Inventors: Henri-Jacques Delecluse, Regina Feederle, Emmalene Bartlett
  • B-cell receptor complex binding proteins containing T-cell epitopes
    Patent number: 10040827
    Abstract: The present invention relates to a polypeptide comprising a) a binding peptide binding to at least one protein selected from the group consisting of CD22, CD19, CD20, and CD21, and b) an immunogenic peptide comprising at least one T-cell epitope for use in vaccination of a subject against B-cell hyperproliferation or for use in the modulation of the immune response in a subject. The present invention further relates to a polynucleotide and a vector encoding said polypeptide and a host cell comprising the same.
    Type: Grant
    Filed: March 19, 2013
    Date of Patent: August 7, 2018
    Assignee: DEUTSCHES KREBSFORSCHUNGSZENTRUM
    Inventors: Henri-Jacques Delecluse, Regina Feederle, Emmalene Bartlett
  • Second generation virus-like particles (VLP) from Epstein-Barr viruses for vaccination purposes
    Patent number: 9517261
    Abstract: The present invention relates to an Epstein-Barr virus-like particle (EB-VLP) substantially free of Epstein-Barr Virus (EBV) DNA. The present invention also relates to a polynucleotide comprising an EBV genome a) lacking at least one expressible gene selected from the group consisting of the BFLF1 gene, the BBRF gene, the BGRF1 gene, the BDRF1 gene, the BALF3 gene, the BFRF1A gene, and the BFRF1 gene, and b) producing the EB-VLP of the invention in a suitable host cell. The present invention further relates to a vector and a host cell comprising the polynucleotide of the invention as well to a method of manufacturing the EB-VLPs, a method of manufacturing a vaccine thereof, a vaccine and a composition comprising the EB-VLPs.
    Type: Grant
    Filed: December 28, 2012
    Date of Patent: December 13, 2016
    Assignee: DEUTSCHES KREBSFORSCHUNGSZENTRUM
    Inventors: Regina Feederle, Sophia Hundt, Henri-Jacques Delecluse
  • Ex vivo method for producing a preparation containing CD4+ T cells specific for EBV structural antigens
    Patent number: 9028840
    Abstract: The present invention discloses an ex vivo method for producing a preparation containing CD4+ T cells specific for EBV structural antigens for use in the prophylaxis and treatment of patients with a reduced T cell activity in order to prevent or treat growth of EBV infected B cells.
    Type: Grant
    Filed: November 27, 2008
    Date of Patent: May 12, 2015
    Assignees: Helmholtz Zentrum Munchen Deutsches Forschungzentrum fur Gesundheit und Umwelt (GmbH), Deutsches Krebsforschungzentrum (DKFZ)
    Inventors: Dinesh Adhikary, Uta Behrends, Josef Mautner, Henri-Jacques Delecluse, Regina Feederle
  • B-CELL RECEPTOR COMPLEX BINDING PROTEINS CONTAINING T-CELL EPITOPES
    Publication number: 20150050279
    Abstract: The present invention relates to a polypeptide comprising a) a binding peptide binding to at least one protein selected from the group consisting of CD22, CD19, CD20, and CD21, and b) an immunogenic peptide comprising at least one T-cell epitope for use in vaccination of a subject against B-cell hyperproliferation or for use in the modulation of the immune response in a subject. The present invention further relates to a polynucleotide and a vector encoding said polypeptide and a host cell comprising the same.
    Type: Application
    Filed: March 19, 2013
    Publication date: February 19, 2015
    Inventors: Henri-Jacques Delecluse, Regina Feederle, Emmalene Bartlett
  • SECOND GENERATION VIRUS-LIKE PARTICLES (VLP) FROM EPSTEIN-BARR VIRUSES FOR VACCINATION PURPOSES
    Publication number: 20140322255
    Abstract: The present invention relates to an Epstein-Barr virus-like particle (EB-VLP) substantially free of Epstein-Barr Virus (EBV) DNA. The present invention also relates to a polynucleotide comprising an EBV genome a) lacking at least one expressible gene selected from the group consisting of the BFLF1 gene, the BBRF gene, the BGRF1 gene, the BDRF1 gene, the BALF3 gene, the BFRF1A gene, and the BFRF1 gene, and b) producing the EB-VLP of the invention in a suitable host cell. The present invention further relates to a vector and a host cell comprising the polynucleotide of the invention as well to a method of manufacturing said EB-VLPs, a method of manufacturing a vaccine thereof, a vaccine and a composition comprising said EB-VLPs.
    Type: Application
    Filed: December 28, 2012
    Publication date: October 30, 2014
    Inventors: Regina Feederle, Sophia Hundt, Henri-Jacques Delecluse
  • EX VIVO METHOD FOR PRODUCING A PREPARATION CONTAINING CD4+ T CELLS SPECIFIC FOR EBV STRUCTURAL ANTIGENS
    Publication number: 20110059133
    Abstract: The present invention discloses an ex vivo method for producing a preparation containing CD4+ T cells specific for EBV structural antigens for use in the prophylaxis and treatment of patients with a reduced T cell activity in order to prevent or treat growth of EBV infected B cells.
    Type: Application
    Filed: November 27, 2008
    Publication date: March 10, 2011
    Applicant: Helmholtz Zentrum Munchen Deutsches Krebsfor schungszentrum Fur Gesundheit Und Unwelt (GMBH)
    Inventors: Dinesh Adhikary, Uta Behrends, Josef Mautner, Henri-Jacques Delecluse, Regina Feederle
  • Recombinanr hhv8 dna
    Publication number: 20030143526
    Abstract: The present invention relates to recombinant HHV8 DNA as well as to methods for the preparation thereof.
    Type: Application
    Filed: January 28, 2003
    Publication date: July 31, 2003
    Inventors: Henri-Jacques Delecluse, Manuela Kost, Wolfgang Hammerschmidt
  • Method for helper virus-free packaging of a gene vector DNA
    Patent number: 6436693
    Abstract: The present invention relates to a method for helper virus-free packaging of gene vector DNA into the virus particles of a DNA virus as well as to eukaryotic helper cells for helper virus-free packaging of gene vector DNA into the virus particles of a DNA helper virus wherein a DNA virus having a genome ≧100 kbp is employed (FIG. 1).
    Type: Grant
    Filed: November 3, 1998
    Date of Patent: August 20, 2002
    Assignee: GSF Forschungszentrum fur Umwelt und Gesundheit GmbH
    Inventors: Henri-Jacques Delecluse, Dagmar Pich, Wolfgang Hammerschmidt
  • DNA virus vectors and methods for their preparation
    Patent number: 6291246
    Abstract: The invention relates to a method for the preparation of DNA virus vectors capable of replication in eukaryotic as well as in prokaryotic cells as well as to DNA virus vectors prepared by this method. Preferably, the method is used to prepare Epstein-Barr virus vectors.
    Type: Grant
    Filed: November 3, 1998
    Date of Patent: September 18, 2001
    Assignee: GSF Forshungszentrum fur Umwelt und Gesundheit GmbH Ingolstradter
    Inventors: Henri-Jacques Delecluse, Dagmar Pich, Wolfgang Hammerschmidt